Company

Bank

Analyst

Coverage

Opinion

Wk chg

4/5 cls

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA)

Piper Jaffray

Charles Duncan

Upgrade

Overweight (from neutral)

3%

$4.56

Duncan also raised his target to $10 from $5 on "enhanced conviction" in the near- and long-term market potential for Alexza's Adasuve Staccato loxapine based on optimism from surveyed physicians. Alexza plans to launch Adasuve in next quarter in the U.S. and EU to treat agitation in adults with schizophrenia or bipolar disorder. Duncan estimates $690,000 in Adasuve sales for 2013 and $29.2M in 2014. Grupo Ferrer Internacional S.A. has commercialization rights in Europe to the loxapine delivered by the Staccato system inhaler.

Biogen Idec Inc. (NASDAQ:BIIB)

Bernstein Research

Geoffrey Porges

Price target

Market perform

0%

$193.31